Testing two new drugs for primary biliary cholangitis
Part of Digestive system clinical trials.
This trial tests a combination of two experimental drugs (seladelpar and cilofexor) for people with primary biliary cholangitis (PBC) who have not responded well to standard treatment. The goal is to see if these drugs can improve liver health and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of primary biliary cholangitis (PBC), a liver disease that damages the bile ducts.
- You need to be on ursodeoxycholic acid (UDCA) for at least 6 months, or you must have tried it in the past and couldn't tolerate it.
- Your alkaline phosphatase (ALP) level must be above 1.67 times the upper limit of normal (a blood test showing liver inflammation).
- You cannot have other causes of liver disease, such as hepatitis, alcoholic liver disease, or fatty liver disease.
- You must not have severe liver cirrhosis with complications like fluid in the belly, bleeding from varices, or a history of liver transplant.
- You must not have taken certain other PBC medications (like obeticholic acid or fibrates) within the last 6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well two medicines, ursodiol and seladelpar, work together for people with primary biliary cholangitis (PBC), a liver disease. It may help doctors understand the best way to treat PBC and improve liver health.
This trial tests a medicine called seladelpar for people with primary biliary cholangitis (PBC) and cirrhosis, a form of liver scarring. The goal is to see if it can help improve liver health and reduce symptoms.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
This trial tests a new oral medication, saroglitazar magnesium, for people with Primary Biliary Cholangitis (PBC) who have not improved enough on standard therapy (UDCA) or cannot tolerate it. The goal is to see if it can help control liver enzymes and improve outcomes.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.